Unilink Bioscientific Remedies Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 10 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -27.49%
- Profit Growth -7.65%
- Ebitda 12.34%
- Net Worth 42.18%
- Total Assets 15.02%
About Unilink Bioscientific Remedies
Unilink Bioscientific Remedies Private Limited (UBRPL) is a Private Limited Indian Non-Government Company incorporated in India on 19 January 2015 and has a history of Ten years and one month. Its registered office is in Pune, Maharashtra, India.
The Company is engaged in the Business Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Ashutosh Kulkarni and Shalaka Gaikwad serve as directors at the Company.
Company Details
- Location
Pune, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74900PN2015PTC153765
- Company No.
153765
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Jan 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Who are the key members and board of directors at Unilink Bioscientific Remedies?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashutosh Kulkarni  | Director | 19-Jan-2015 | Current |
| Shalaka Gaikwad | Director | 05-Aug-2017 | Current |
Financial Performance of Unilink Bioscientific Remedies.
Unilink Bioscientific Remedies Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 27.49% decrease. The company also saw a slight decrease in profitability, with a 7.65% decrease in profit. The company's net worth Soared by an impressive increase of 42.18%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Unilink Bioscientific Remedies?
Unlock access to Unilink Bioscientific Remedies's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Unilink Bioscientific Remedies?
Unlock and access historical data on people associated with Unilink Bioscientific Remedies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Unilink Bioscientific Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Unilink Bioscientific Remedies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
